All 22 participants had previously been treated with a GLP-1 therapy for durations ranging from approximately 5 months to 5 years, with a mean total body weight loss of 24% while on therapy and a mean body weight of 80 kg 3 kg (SEM) at the time of intervention
Diabetes 61:12431249 Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
Study of -Amyrin targeting Sirt1/PGC-1/PPAR axis to regulate fatty acid metabolism against liver fibrosis, Phytomedicine, 159 , (158432), (2026)
Statins remain first-line treatment for elevated cholesterol, with GLP-1 therapy providing complementary cardiovascular benefits
Make sure you keep those tabs out of your dogs reach, because the consequences if a pet eats one can be severe
Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors